We found that the addition of L-NAME to Poly6-treated DC2.4 cells led to the inhibition of the oncolytic activity of Poly6 in various cancer cell lines, including MC38, B16F10, and EO771 (Figure 5B and Figure S8D), suggesting that Poly6-treated DCs elicit anticancer effects via the iNOS-NO axis. The gene discussed is NOS2; the disease is cancer.